Advertisement
Advertisement

ALNY

ALNY logo

Alnylam Pharmaceuticals, Inc.

452.05
USD
+0.33
+0.07%
Sep 18, 15:59 UTC -4
Closed
exchange

After-Market

455.90

+3.85
+0.85%

Alnylam Pharmaceuticals, Inc. Profile

About

Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic disease and hepatic infectious disease. The company's lead drug-Onpattro received regulatory approvals in the United States and Europe for the treatment of hereditary transthyretin-mediated amyloidosis in adults. The FDA approved Givlaari for acute hepatic porphyria. The FDA approved Oxlumo injection for subcutaneous use, for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients. Moreover, the company is evaluating inclisiran for hypercholesterolemia in partnership with The Medicines Company acquired by Novartis. The FDA approved Leqvio to reduce low-density lipoprotein cholesterol with two doses a year..

Info & Links

CEO

Yvonne L. Greenstreet

Headquarters

675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE
CAMBRIDGE, MA 02142, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.alnylam.com

Auditor

PricewaterhouseCoopers LLP

Share holders

26

Employees

2,230

Alnylam Pharmaceuticals, Inc. Statistics

Valuation Measures

Market Capitalization2

59.76B

Enterprise Value

59.67B

Enterprise Value/EBITDA(ttm)

-482.44

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

24.56

Price to Book(mrq)

241.26

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

83.77%

Operating Margin(ttm)

-12.93%

Profit Margin(ttm)

-13.66%

Return on Equity(ttm)

-273.52%

Return on Invested Capital(ttm)

-28.47%

Return on Assets(ttm)

-7.39%

Income Statement

Revenue(ttm)

2.46B

Revenue Per Share(ttm)

18.78

Gross Profit(ttm)

2.06B

EBITDA(ttm)3

-123.69M

Net Income Available to Common(ttm)

-319.09M

Diluted EPS(ttm)

-2.47

Share Statistics

Beta (5Y Monthly)

0.32

52-Week Change

64.71%

S&P 500 52-Week Change

16.07%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

131.08M

Dividend Yield

0.00%

Float4

129.11M

% Held by Insiders

1.50%

% Held by Institutions

92.97%

Balance Sheet

Total Cash(mrq)

2.86B

Total Cash Per Share(mrq)

21.80

Total Debt(mrq)

1.03B

Total Debt/Equity(mrq)

409.64%

Current Ratio(mrq)

2.80%

Quick Ratio(mrq)

2.75%

Book Value Per Share(mrq)

1.91

Cash Flow

Operating Cash Flow Per Share(ytd)

0.27

Free Cash Flow(ytd)

12.15M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement